Marijo Hanson, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 3082 Mcmurray Dr, Anderson, CA 96007 Phone: 305-365-4420 Fax: 530-365-5186 |
Mr. Ron Frank Poli, P.A. Physician Assistant Medicare: Medicare Enrolled Practice Location: 2760 N. Balls Ferry Rd., Anderson, CA 96007 Phone: 530-365-4412 Fax: 530-365-5186 |
Mrs. Lisa Ann Henn, P.A. Physician Assistant - Medical Medicare: Not Enrolled in Medicare Practice Location: 3082 Mcmurray Dr, Anderson, CA 96007 Phone: 530-365-4420 Fax: 530-365-5186 |
Andrew Hansen, Physician Assistant Medicare: Medicare Enrolled Practice Location: 2965 East St, Anderson, CA 96007 Phone: 661-204-6372 |
News Archive
Today's headlines include reports about immigrant patients' health care as well as the coverage limits that some victims of the Boston Marathon bombings might face.
Higher mortality rates among older adult asthma patients compared to their younger counterparts may be due, at least in part, to an increase in airway inflammation, according to a study conducted by researchers in Canada, who note that their results imply that elderly patients are either less likely to follow asthma medication dosing instructions, or that the underlying airway inflammation in elderly patients is relatively resistant to current anti-inflammatory therapies.
National HealthCare Corporation and TriStar Health announce an alliance that aims to provide patients across Middle Tennessee with a continually higher level of care as they transition from hospitals to recovery.
Complementary and alternative medicine may give allergy and asthma sufferers new options for treating symptoms, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16. Allergists discussed how herbal treatments may be integrated into conventional allergy treatments, including a novel Chinese herbal formula for treating all types of food allergies.
Portola Pharmaceuticals and Merck, known as MSD outside the United States and Canada, today announced that Merck plans to return to Portola all rights for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation (SPAF). This decision was made following a review of Merck's investigational portfolio.
› Verified 9 days ago